Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Identifieur interne : 003E05 ( Main/Exploration ); précédent : 003E04; suivant : 003E06Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Auteurs : RBID : pubmed:9669389English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Bispecific (diagnostic use), Carcinoembryonic Antigen (immunology), Carcinoma, Medullary (radionuclide imaging), Carcinoma, Medullary (secondary), Carcinoma, Medullary (surgery), Female, Haptens (diagnostic use), Humans, Indium Radioisotopes (diagnostic use), Intraoperative Care, Liver Neoplasms (radionuclide imaging), Liver Neoplasms (secondary), Liver Neoplasms (surgery), Male, Middle Aged, Neoplasm Recurrence, Local (radionuclide imaging), Pentetic Acid (diagnostic use), Radioimmunodetection (methods), Radionuclide Imaging (instrumentation), Sensitivity and Specificity, Thyroid Neoplasms (radionuclide imaging), Thyroid Neoplasms (surgery), Tumor Markers, Biological (blood).
- MESH :
- chemical , blood : Tumor Markers, Biological.
- chemical , diagnostic use : Antibodies, Bispecific, Haptens, Indium Radioisotopes, Pentetic Acid.
- chemical , immunology : Carcinoembryonic Antigen.
- instrumentation : Radionuclide Imaging.
- methods : Radioimmunodetection.
- radionuclide imaging : Carcinoma, Medullary, Liver Neoplasms, Neoplasm Recurrence, Local, Thyroid Neoplasms.
- secondary : Carcinoma, Medullary, Liver Neoplasms.
- surgery : Carcinoma, Medullary, Liver Neoplasms, Thyroid Neoplasms.
- Adult, Aged, Female, Humans, Intraoperative Care, Male, Middle Aged, Sensitivity and Specificity.
Abstract
Pretargeting labeled bivalent hapten with bispecific antibodies has proven feasible in the clinic, and our earlier results have suggested the technique may be very sensitive for detecting small recurrences and metastases. Medullary thyroid carcinoma (MTC) is an example where this technique may be the most useful since local recurrences and isolated metastases are removed surgically when detected, and thyrocalcitonin provides a specific and sensitive tumor marker. In our current study, we evaluated pretargeted immunoscintigraphy in a larger number of MTC patients.
PubMed: 9669389
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.</title><author><name sortKey="Barbet, J" uniqKey="Barbet J">J Barbet</name><affiliation wicri:level="1"><nlm:affiliation>Immunotech S.A., Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Immunotech S.A., Marseille</wicri:regionArea><placeName><region type="région">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Peltier, P" uniqKey="Peltier P">P Peltier</name></author><author><name sortKey="Bardet, S" uniqKey="Bardet S">S Bardet</name></author><author><name sortKey="Vuillez, J P" uniqKey="Vuillez J">J P Vuillez</name></author><author><name sortKey="Bachelot, I" uniqKey="Bachelot I">I Bachelot</name></author><author><name sortKey="Denet, S" uniqKey="Denet S">S Denet</name></author><author><name sortKey="Olivier, P" uniqKey="Olivier P">P Olivier</name></author><author><name sortKey="Leccia, F" uniqKey="Leccia F">F Leccia</name></author><author><name sortKey="Corcuff, B" uniqKey="Corcuff B">B Corcuff</name></author><author><name sortKey="Huglo, D" uniqKey="Huglo D">D Huglo</name></author><author><name sortKey="Proye, C" uniqKey="Proye C">C Proye</name></author><author><name sortKey="Rouvier, E" uniqKey="Rouvier E">E Rouvier</name></author><author><name sortKey="Meyer, P" uniqKey="Meyer P">P Meyer</name></author><author><name sortKey="Chatal, J F" uniqKey="Chatal J">J F Chatal</name></author></titleStmt><publicationStmt><date when="1998">1998</date><idno type="RBID">pubmed:9669389</idno><idno type="pmid">9669389</idno><idno type="wicri:Area/Main/Corpus">004087</idno><idno type="wicri:Area/Main/Curation">004087</idno><idno type="wicri:Area/Main/Exploration">003E05</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Bispecific (diagnostic use)</term><term>Carcinoembryonic Antigen (immunology)</term><term>Carcinoma, Medullary (radionuclide imaging)</term><term>Carcinoma, Medullary (secondary)</term><term>Carcinoma, Medullary (surgery)</term><term>Female</term><term>Haptens (diagnostic use)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Intraoperative Care</term><term>Liver Neoplasms (radionuclide imaging)</term><term>Liver Neoplasms (secondary)</term><term>Liver Neoplasms (surgery)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (radionuclide imaging)</term><term>Pentetic Acid (diagnostic use)</term><term>Radioimmunodetection (methods)</term><term>Radionuclide Imaging (instrumentation)</term><term>Sensitivity and Specificity</term><term>Thyroid Neoplasms (radionuclide imaging)</term><term>Thyroid Neoplasms (surgery)</term><term>Tumor Markers, Biological (blood)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Tumor Markers, Biological</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Bispecific</term><term>Haptens</term><term>Indium Radioisotopes</term><term>Pentetic Acid</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Carcinoembryonic Antigen</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunodetection</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Medullary</term><term>Liver Neoplasms</term><term>Neoplasm Recurrence, Local</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Carcinoma, Medullary</term><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Carcinoma, Medullary</term><term>Liver Neoplasms</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Intraoperative Care</term><term>Male</term><term>Middle Aged</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pretargeting labeled bivalent hapten with bispecific antibodies has proven feasible in the clinic, and our earlier results have suggested the technique may be very sensitive for detecting small recurrences and metastases. Medullary thyroid carcinoma (MTC) is an example where this technique may be the most useful since local recurrences and isolated metastases are removed surgically when detected, and thyrocalcitonin provides a specific and sensitive tumor marker. In our current study, we evaluated pretargeted immunoscintigraphy in a larger number of MTC patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">9669389</PMID><DateCreated><Year>1998</Year><Month>08</Month><Day>11</Day></DateCreated><DateCompleted><Year>1998</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0161-5505</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>7</Issue><PubDate><Year>1998</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.</ArticleTitle><Pagination><MedlinePgn>1172-8</MedlinePgn></Pagination><Abstract><AbstractText Label="UNLABELLED">Pretargeting labeled bivalent hapten with bispecific antibodies has proven feasible in the clinic, and our earlier results have suggested the technique may be very sensitive for detecting small recurrences and metastases. Medullary thyroid carcinoma (MTC) is an example where this technique may be the most useful since local recurrences and isolated metastases are removed surgically when detected, and thyrocalcitonin provides a specific and sensitive tumor marker. In our current study, we evaluated pretargeted immunoscintigraphy in a larger number of MTC patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Anti-carcinoembryonic antigen (CEA) x anti-diethylenetriaminepentaacetic acid (DTPA) indium bispecific antibody and 111In-labeled bivalent DTPA hapten were administered sequentially (4-5 days apart) to 44 patients with elevated circulating calcitonin after resection of primary MTC. Immunoscintigraphy was performed 2, 5 and 24 hr after hapten injection and, when necessary, at longer time intervals. When available, a handheld gamma probe was used during surgery.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifteen patients had known tumor sites before immunoscintigraphy. Tumors were imaged in 12 (80%) of these patients, including 3 with liver metastases. Five unknown tumor sites were detected. For the 29 patients with occult disease, immunoscintigraphy detected high-activity uptake sites in 21 patients (72%), including 5 in the liver. Twelve were confirmed by surgery, 1 by guided morphologic imaging and 1 by venous catheterization. There were 2 false-positive patients. The other 5 patients have not yet been confirmed. All detected liver metastases were high-activity uptake areas. Radioimmunoguided surgery was used in 14 patients. It was considered helpful by the surgeon in 12 patients, including 4 patients where it determined the resection of small, not palpable nor visible, tumor-involved lymph nodes. Surgical resection resulted in a significant decrease (8 patients) or normalization (1 patient) of circulating calcitonin and CEA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This technique affords high sensitivity and specificity for detecting small tumor lesions including liver metastases. Its use for immunoscintigraphy and guided surgery should improve the therapeutic management of recurrent MTC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>J</ForeName><Initials>J</Initials><Affiliation>Immunotech S.A., Marseille, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Peltier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bardet</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Bachelot</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Denet</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Olivier</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Leccia</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Corcuff</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Huglo</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Proye</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rouvier</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Multicenter Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Haptens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Tumor Markers, Biological</NameOfSubstance></Chemical><Chemical><RegistryNumber>7A314HQM0I</RegistryNumber><NameOfSubstance>Pentetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Medullary</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Haptens</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Intraoperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pentetic Acid</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunodetection</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tumor Markers, Biological</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>7</Month><Day>21</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>7</Month><Day>21</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9669389</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9669389
|texte= Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9669389" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |